Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 314

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 19
Chunk 314
---
─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  On December 1, 2020, the Company entered into a clinical trial agreement with Cambridge University Hospitals                              
  NHS Trust, wherein Cambridge will receive 5% of any marginal increase in the Company’s net sales (all as defined in the agreement)        
  generated on account of any patent or patent claim granted from the research performed in such trial, and 2% of the Company’s net         
  sales (minus the aforementioned marginal increase payment) received for the treatment of Squamous Cell Carcinoma of the vulva, for three  
  years from the date of first sale, world-wide.                                                                                            
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

F-24

ALPHA TAU MEDICAL
LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS

U. S. dollars
in thousands (except share and per share data)

NOTE 11:- COMMITMENTS AND CONTINGENT LIABILITIES (Cont.)

  On August 16, 2022, the Company entered into a collaboration agreement with MIM Software, Inc. (“ MIM”)                                      
  to provide treatment planning software for clinical sites using the Alpha DaRT therapy. Under the terms of the agreement, the parties        
  will collaborate on the use of MIM’s software suite, including MIM Symphony® and MIMcloud®, for development of new features                  
  and support for the Alpha DaRT across multiple potential indications, integration into all clinical trials involving the Alpha DaRT, and     
  bundling the MIM software with the Alpha DaRT for future commercial sales in territories where the Alpha DaRT and MIM’s software             
  are both approved. The agreement contemplates certain payments to MIM to be agreed between the parties upon initiating certain workstreams,  
  as well as payments to MIM upon commercial sale of the Alpha DaRT bundled with MIM’s software products.                                      
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

NOTE 12:- SHAREHOLDERS’ (DEFICIENCY) EQUITY

  Share capital:  

Stock split

On July 6, 2021,
the Company’s board of directors approved a1: 0.905292stock split which was effected on March 7, 2022